Low-dose decitabine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation

Relapse is the major cause of mortality in patients with acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Effective preventive intervention in high-risk AML may be crucial. In this study, we investigated the clinical efficacy and safety of low dose d...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bone marrow transplantation (Basingstoke) 2021-07, Vol.56 (7), p.1674-1682
Hauptverfasser:	Tang, Xiaowen, Valdez, Benigno C., Ma, Yunju, Zhang, Qianqian, Qu, Changju, Dai, Haiping, Yin, Jia, Li, Zheng, Xu, Ting, Xu, Yang, Chen, Jia, Zhu, Xiaming, Chen, Zixing, Wu, Depei, Andersson, Borje S.
Format:	Artikel
Sprache:	eng
Schlagworte:	5-aza-2'-deoxycytidine 692/699/1541/1990/283/1897 692/699/67/1990/283/1897 Acute myeloid leukemia Biophysics Busulfan Cell Biology Conditioning Cyclophosphamide Decitabine Dosage and administration Graft vs Host Disease Hematology Hematopoietic Stem Cell Transplantation Hematopoietic stem cells Humans Immunology Internal Medicine Leukemia Leukemia, Myeloid, Acute - therapy Life Sciences & Biomedicine Medicine Medicine & Public Health Myeloid leukemia Oncology Prospective Studies Public Health Retrospective Studies Risk Science & Technology Stem cell transplantation Stem Cells Survival Transplantation Transplantation Conditioning
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!